NASDAQ:EXEL
Exelixis Stock News
$22.15
+0.250 (+1.14%)
At Close: May 07, 2024
Parametric Portfolio Associates LLC Has $8.05 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)
07:45am, Thursday, 18'th Jun 2020
Parametric Portfolio Associates LLC increased its position in Exelixis, Inc. (NASDAQ:EXEL) by 12.6% during the first quarter, according to the company in its most recent 13F filing with the Securities
Exelixis to Webcast Virtual Fireside Chat as Part of the BofA Securities Napa Biopharma Conference on June 24, 2020
12:00am, Thursday, 18'th Jun 2020
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will participate
3 Stocks Growing Capex Fast
05:42pm, Wednesday, 17'th Jun 2020
Large spending to improve fixed assets may anticipate growth Continue reading...
Biotech ETFs: Appraising The Pipelines
12:00am, Wednesday, 17'th Jun 2020
Parsing the performance and holdings of different biotech funds.
Viela Bio Gets Approval And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:VIE)
09:13am, Tuesday, 16'th Jun 2020
Viela Bio receives FDA approval for Uplizna. Exelixis starts late stage lung cancer study. Agios reports positive proof of concept study.
Exelixis: Defying Corona Bear Market Expectations (NASDAQ:EXEL)
11:45am, Monday, 15'th Jun 2020
Exelixis recently presented robust Phase 3 data for CheckMate-9ER, which galvanized a substantial rally. Riding strong fundamental development, Exelixis posted
20,735 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by AlphaCrest Capital Management LLC
08:03am, Sunday, 14'th Jun 2020
AlphaCrest Capital Management LLC purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange
Hedge Funds Going Back and Forth About Exelixis, Inc. (EXEL)
02:15pm, Friday, 12'th Jun 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filing
Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-01, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with
Exelixis Inc (EXEL) CEO Michael Morrissey Presents at Goldman Sachs Global Healthcare Conference (Transcript)
05:44am, Thursday, 11'th Jun 2020
Exelixis Inc (NASDAQ:EXEL) Goldman Sachs Global Healthcare Conference June 10, 2020 2:10 PM ET Company Participants Michael Morrissey - President & CEO Conf
Exelixis, Inc. (NASDAQ:EXEL) Holdings Decreased by Sowell Financial Services LLC
06:16am, Wednesday, 10'th Jun 2020
Sowell Financial Services LLC lessened its stake in Exelixis, Inc. (NASDAQ:EXEL) by 34.6% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The insti
Physicians’ Education Resource® Launches “Oncology NOW” Webcast Series
12:00am, Friday, 05'th Jun 2020
Physicians’ Education Resource® Launches “Oncology NOW” Webcast Series
Exelixis (EXEL) Down 11.5% Since Last Earnings Report: Can It Rebound?
03:31pm, Thursday, 04'th Jun 2020
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
08:05pm, Wednesday, 03'rd Jun 2020
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in June:
Edited Transcript of EXEL earnings conference call or presentation 5-May-20 9:00pm GMT
06:59am, Tuesday, 02'nd Jun 2020
Q1 2020 Exelixis Inc Earnings Call
